logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
F

Fiona Simpkins

University of Pennsylvania
H指数:35
被引数:3,875

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace

空间和时间定义的蒙特卡洛剂量学解释了在砹211-ParaThanatrace靶向α粒子疗法中的卵巢癌细胞存活率

International Journal of Radiation Oncology*Biology*Physics
IF0
2025-06-210
PRE
Victor V. Onecha; Daniel Suarez-García; Jesús J. Bosque; Hwan Lee; Fiona Simpkins; Sarah B. Gitto; Daniel A. Pryma; Alejandro Bertolet
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR

靶向CCNE1扩增的卵巢癌和子宫内膜癌，通过联合抑制PKMYT1和ATR

NATURE COMMUNICATIONS
IF15.7
2025-04-010
OA
Xu, Haineng; George, Erin; Gallo, David; Medvedev, Sergey; Wang, Xiaolei; Datta, Arindam; Kryczka, Rosie; Hyer, Marc L.; Fourtounis, Jimmy; Stocco, Rino; Aguado-Fraile, Elia; Petrone, Adam; Yin, Shou Yun; Shiwram, Ariya; Liu, Fang; Anderson, Matthew; Kim, Hyoung; Greenberg, Roger A.; Marshall, C. Gary; Simpkins, Fiona
Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis

Olaparib通过BRCA突变和同源重组缺陷治疗铂敏感复发性卵巢癌: 2期光研究最终总生存分析

CANCER
IF5.1
2025-01-160
OAAI
Liu, Ying L.; Mathews, Cara A.; Simpkins, Fiona; Cadoo, Karen A.; Provencher, Diane; Mccormick, Colleen C.; Elnaggar, Adam C.; Altman, Alon D.; Gilbert, Lucy; Black, Destin; Kabil, Nashwa; Taylor, Rosie N.; Barnicle, Alan; Munley, Jiefen Y.; Aghajanian, Carol
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

Cyclin E1/CDK2的激活定义了妇科癌症中WEE1激酶抑制的关键易损性。

NPJ PRECISION ONCOLOGY
IF8
2025-01-040
OA
Kim, Daehwan; Chung, Heekyung; Liu, Wen; Jeong, Kangjin; Ozmen, Tugba Y.; Ozmen, Furkan; Rames, Matthew J.; Kim, Sangyub; Guo, Xiao; Jameson, Nathan; de Jong, Petrus R.; Yea, Steven; Harford, Laurie; Li, Jiali; Mathews, Cara A.; Doroshow, Deborah B.; Charles, Vincent J.; Kim, Doris; Fischer, Kimberlee; Samatar, Ahmed A.; Jubb, Adrian; Bunker, Kevin D.; Blackwell, Kimberly; Simpkins, Fiona; Meric-Bernstam, Funda; Mills, Gordon B.; Harismendy, Olivier; Ma, Jianhui; Lackner, Mark R.
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib

在评估奥拉帕尼的六项临床试验中，超过2000名卵巢癌患者的基因组不稳定性模式

GENOME MEDICINE
IF11.2
2024-12-180
OA
Barnicle, Alan; Ray-Coquard, Isabelle; Rouleau, Etienne; Cadoo, Karen; Simpkins, Fiona; Aghajanian, Carol; Leary, Alexandra; Poveda, Andres; Lheureux, Stephanie; Pujade-Lauraine, Eric; You, Benoit; Ledermann, Jonathan; Matulonis, Ursula; Gourley, Charlie; Timms, Kirsten M.; Lai, Zhongwu; Hodgson, Darren R.; Elks, Cathy E.; Dearden, Simon; Egile, Coumaran; Lao-Sirieix, Pierre; Harrington, Elizabeth A.; Brown, Jessica S.
[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status

[18F]Fluorthanatrace PET在卵巢癌中的应用：与[18F]FDG PET、病灶位置、肿瘤分级和乳腺癌基因突变状态的比较

JOURNAL OF NUCLEAR MEDICINE
IF9.1
2024-12-050
PRE
Weeks, Joanna K.; Pantel, Austin R.; Gitto, Sarah B.; Liu, Fang; Schubert, Erin K.; Pryma, Daniel A.; Farwell, Michael D.; Mankoff, David A.; Mach, Robert H.; Simpkins, Fiona; Lin, Lilie L.
Individualised schedule optimisation improves rates and severity of anaemia in patients ( pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
EUROPEAN JOURNAL OF CANCER
IF7.1
2024-10-010
PRE
Hojgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; Sethuraman, S.; Soria-Bretones, I.; Liu, Y.; Sun, X.; Hawkey, N.; Basciano, P.; Unger, T. J.; Bacque, E. S.; Schram, A.
MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-015
PRE
Yap, Timothy A.; Schram, Alison; Lee, Elizabeth K.; Simpkins, Fiona; Weiss, Mia C.; LoRusso, Patricia; Hojgaard, Martin; Carneiro, Benedito A.; Moy, Ryan H.; Garrido-Laguna, Ignacio; Koehler, Maria; Unger, Thaddeus J.; Bacque, Emeline; Aguado-Fraile, Elia; Sethuraman, Sunantha; Dhake, Snehal; Liu, Yajun; Fretland, Adrian J.; Sun, Xizi; Xu, Yi; Hawkey, Nathan; Truong, Jen; Lheureux, Stephanie
Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancer
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Kinose, Yasuto; Xu, Haineng; Kumar, Sushil; Kim, Hyoung; Medvedev, Sergey; Wang, Xiaolei; George, Erin; Shan, Xiaoyin; Gitto, Sarah; D'Andrea, Kurt; Wubbenhorst, Bradley; Whicker, Margaret; Hallberg, Dorothy; Schwartz, Lauren; Nathanson, Katherine L.; Mills, Gordon; Velculescu, Victor E.; Wang, Tian-Li; Brown, Eric; Drapkin, Ronny; Simpkins, Fiona
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
TARGETED ONCOLOGY
IF4
2023-06-0616
OAAI
Bauer, Todd M.; Moore, Kathleen N.; Rader, Janet S.; Simpkins, Fiona; Mita, Alain C.; Beck, J. Thaddeus; Hart, Lowell; Chu, Quincy; Oza, Amit; Tinker, Anna V.; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Mugundu, Ganesh; Jenkins, Suzanne; Chmielecki, Juliann; Jones, Suzanne; Spigel, David; Fu, Siqing

研究方向

暂未获取到该数据
E
Eric J. Brown
H 指数:90论文数:390被引数:2.6万
E
Erin George
H 指数:14论文数:72被引数:1,267
H
Hyoung Kim
H 指数:24论文数:165被引数:2,605
G
Gordon B. Mills
H 指数:231论文数:3,475被引数:26.3万
R
Robert H. Mach
H 指数:64论文数:684被引数:1.8万
L
Lilie L. Lin
H 指数:32论文数:259被引数:3,815
S
Sergey Medvedev
H 指数:14论文数:59被引数:1,289
S
Sarah B. Gitto
H 指数:15论文数:135被引数:646
D
David A. Mankoff
H 指数:82论文数:598被引数:2.0万
M
Mehran Makvandi
H 指数:23论文数:147被引数:1,763